Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients

Authors

Jennifer Trofe-Clark, University of Pennsylvania
Daniel C Brennan, Washington University School of Medicine in St. Louis
Patricia West-Thielke, University of Illinois at Chicago
Michael C Milone, University of Pennsylvania
Mary Ann Lim, University of Pennsylvania
Robin Neubauer, University of Pennsylvania
Vincenza Nigro, Veloxis Pharmaceuticals
Roy D Bloom, University of Pennsylvania

Journal

American Journal of Kidney Diseases

Publication Date

3-1-2018

Volume

71

Issue

3

First Page

315

Last Page

326

Document Type

Open Access Publication

DOI

10.1053/j.ajkd.2017.07.018

Rights and Permissions

Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2018 Mar;71(3):315-326. doi: 10.1053/j.ajkd.2017.07.018. © 2017 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Trofe-Clark, Jennifer; Brennan, Daniel C; West-Thielke, Patricia; Milone, Michael C; Lim, Mary Ann; Neubauer, Robin; Nigro, Vincenza; and Bloom, Roy D, "Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients." American Journal of Kidney Diseases. 71, 3. 315 - 326. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8354